Waters Corp

Waters Corp(WAT)股票分析

$414.690

-6.469 (-1.56%)收盤時

Loading chart…
High
422.500
Open
417.800
VWAP
416.52
Vol
435.14K
Mkt Cap
16.99B
Low
412.380
Amount
181.25M
EV/EBITDA, TTM
35.35

Waters Corporation is a global life sciences and diagnostics company. The Company offers analytical instruments, separations technologies, and software, serving life, materials, food, and environmental sciences. Its segments include Waters and TA. The Company primarily designs, manufactures, sells and services high-performance liquid chromatography (HPLC), ultra-performance liquid chromatography (UPLC and together with HPLC, referred to as LC) and mass spectrometry (MS) technology systems and support products, including chromatography columns, other consumable products and comprehensive post-warranty service plans. The Company designs, manufactures, sells and services thermal analysis, rheometry and calorimetry instruments through its TA Instruments (TA) product line. The Company is also a developer and supplier of advanced software-based products that interface with the Company’s instruments, as well as other manufacturers’ instruments.

AI analysis of Waters Corp (WAT)

buy

Waters Corp is a good buy right now due to its recent strong earnings report showing Q2 2026 revenue of $1.645 billion, a 7% year-over-year increase, and an upgraded analyst price target of $480, which suggests significant upside from the current price of $414.69. However, a risk to consider is the recent negative net income reported for Q1 and Q2 of 2026, which was -72 million and -136 million USD, respectively.

Analyst Ratings (15)

-0.15% downside
Hold
5 Buy
9 Hold
1 Sell
Current: 414.69
最低
350.00
平均
414.08
最高
480.00

Piper Sandler

2026-08-27

目標價

$480

Overweight

Citi

2026-08-10

目標價

$470

Buy

Morgan Stanley

2026-08-05

目標價

$430

Equal Weight

Deutsche Bank

2026-08-05

目標價

$400

Hold

Barclays

2026-08-05

目標價

$460

Overweight

估值指標

The current forward P/E ratio for Waters Corp (WAT) is 29.07, compared to its 5-year average forward P/E of 25.97.

Forward P/E

Fair
5Y Average P/E
25.97
Current P/E
29.07
高估
29.62
低估
22.32

Forward EV/EBITDA

Overvalued
5Y Average EV/EBITDA
21.59
Current EV/EBITDA
35.35
高估
33.58
低估
9.60

Forward P/S

Fair
5Y Average P/S
6.18
Current P/S
5.71
高估
7.23
低估
5.14

Alphio AI Price Scenarios for WAT

Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.

B

Bull

Bull · 25%WAT

$494.79

情境價格

B

Base

Base · 50%WAT

$430.97

情境價格

B

Bear

Bear · 25%WAT

$340.64

情境價格

Whales holding WAT

I

Integral Health Asset Management, LLC

+ HoldingWAT

+15.08%

3M Return

A

Armistice Capital LLC

+ HoldingWAT

+13.92%

3M Return

B

Beck, Mack & Oliver LLC

+ HoldingWAT

+8.98%

3M Return

B

BLI - Banque De Luxembourg Investments S.A.

+ HoldingWAT

+6.38%

3M Return

V

Veritas Asset Management LLP

+ HoldingWAT

+5.80%

3M Return

A

Aviso Wealth Inc.

+ HoldingWAT

+5.73%

3M Return

事件時間軸

2026-08-04 (ET)

09:00:00

Palantir Surges 15% After Earnings Beat Expectations

07:30:00

Waters Corporation Reports Q2 Revenue of $1.65B, Beating Expectations

07:30:00

Waters Raises FY26 Revenue Outlook to $6.42B-$6.48B

07:30:00

Company Sees Q3 Revenue of $1.75B-$1.6B

2026-06-24 (ET)

09:01:00

IMU Biosciences Partners with Waters Corporation for AI Immunology Platform

資訊

WAT FAQ — answered by Alphio AI

Waters Corporation is a global life sciences and diagnostics company. The Company offers analytical instruments, separations technologies, and software, serving life, materials, food, and environmental sciences. Its segments include Waters and TA. The Company primarily designs, manufactures, sells and services high-performance liquid chromatography (HPLC), ultra-performance liquid chromatography (UPLC and together with HPLC, referred to as LC) and mass spectrometry (MS) technology systems and support products, including chromatography columns, other consumable products and comprehensive post-warranty service plans. The Company designs, manufactures, sells and services thermal analysis, rheometry and calorimetry instruments through its TA Instruments (TA) product line. The Company is also a developer and supplier of advanced software-based products that interface with the Company’s instruments, as well as other manufacturers’ instruments. It operates in the Healthcare sector (LABORATORY ANALYTICAL INSTRUMENTS industry).

Waters Corp is a good buy right now due to its recent strong earnings report showing Q2 2026 revenue of $1.645 billion, a 7% year-over-year increase, and an upgraded analyst price target of $480, which suggests significant upside from the current price of $414.69. However, a risk to consider is the recent negative net income reported for Q1 and Q2 of 2026, which was -72 million and -136 million USD, respectively.

15 analysts cover WAT: 5 rate it Buy, 9 Hold and 1 Sell. The average price target is 414.08.

本頁僅供研究參考,不構成投資建議。模型可能出錯。過往表現不代表未來結果。

免費開始